Natural History of Post-Transfusion Non-A, Non-B Hepatitis

2014-08-27 03:57:53 | BioPortfolio


To compare the clinical, biochemical, and histological status of Non-A, Non-B post-transfusion hepatitis patients with that of patients who did not develop post-transfusion hepatitis.



Hepatitis following the transfusion of blood and blood products continues to be an important problem, despite routine hepatitis surface antigen (HBsAg) screening of donor blood. In the mid 1980s, seven to ten percent of transfused individuals developed post-transfusion hepatitis (PTH). The majority of the cases were ascribed to the virus(es) of NANB hepatitis. Because the viral agent or agents responsible for this disease had not been identified in 1988, it was not possible to prevent the illness. There was evidence that the incidence of NANB PTH could be reduced by the use of volunteer donor blood instead of commercial blood. Other measures, in the absence of a specific test, related to efforts to develop a surrogate test to screen donor blood. The most promising approach in 1988 was to measure ALT activity and to exclude donors with increased levels of the enzyme. The measurement of antihepatitis-B core antigen (anti-HBc) was another surrogate test that appeared to be useful. Acute hepatitis caused by this agent(s) is mild and often asymptomatic, although in rare instances fulminant hepatitis may result and indeed may be associated with a higher mortality than that occurring in the course of acute hepatitis A or B.

Of greater concern was the finding that chronic hepatitis appeared to be a common outcome of acute NANB PTH. Chronic NANB hepatitis was defined as the presence of chronic liver disease in a patient who was negative for the serologic markers of hepatitis B virus, hepatitis A virus, cytomegalovirus, and Epstein-Barr virus, and who did not have a history of drug toxicity, alcoholism, or heart failure.

It appeared likely that chronic liver disease occurred at least as commonly, and perhaps more commonly, following infection with the NANB virus(es) than with the hepatitis B virus. Furthermore, evidence suggested that the presumed serious histopathologic abnormalities of chronic active hepatitis and cirrhosis were also more common.

The chronic sequelae of NANB hepatitis infection may therefore be more important than the acute illness. That information was of profound importance to blood bankers. Because the most disturbing data had been derived primarily from isolated studies, suggesting possible regional overtones or an effect of large volume transfusion, it seemed appropriate to study the problem of chronic NANB hepatitis on a wider scale.


The design was that of a retrospective, prospective study which followed two previously studied cohorts. In Phase I, evidence was presented that subjects in the Transfusion-Transmitted Virus Study and the Veterans Administration Cooperative Study of Post-transfusion Hepatitis could be located and their current status established. Initiation of Phase II was dependent on successful completion of Phase I.

In Phase II, medical records of all individuals identified in Phase I were obtained. The records were examined for clinical morbidity and mortality with particular attention given to liver-related abnormalities. Death certificates were sought for deceased patients. All surviving patients in the control and case groups were invited to participate and were re-evaluated and followed prospectively. Controls were matched for age, race, gender, and number of units of blood product received. Initial re-evaluation consisted of a medical history, physical examination, and a series of biochemical tests for evidence of chronic liver disease. In the initial evaluation, survivors were compared for clinical evidence of chronic liver disease, biochemical, and special test evidence of chronic liver disease.

In Phase III, all subjects from both groups were followed for six months by biochemical screening, including aminotransferase (ALT) and aspartate aminotransferase (AST). Enzyme assays were performed at least three times, thirty days apart. If aminotransferase activity was persistently abnormal, a liver biopsy was performed. The initial six month follow-up was designed to detect chronic liver disease. Once evidence of chronic liver disease had been established, those patients with chronic liver disease and controls were re-evaluated for evidence of liver disease at six-month intervals for three years from the initial visit.

The study was renewed in 1993 in order to develop a protocol and manual of operations for continuation of the study on the long- term follow-up of transfusion-associated non-A,non-B (NANB) hepatitis; to conduct annual National Death Index (NDI) searches for all cohort members who were alive or not located at last follow-up; to obtain and code death certificates for all newly deceased; and to collect and abstract medical records for all hospitalizations that occurred since the last follow-up for newly deceased subjects. The searches were conducted to determine whether a mortality difference between the infected cohort and the controls would develop with longer observation, as was suggested by the continued presence of chronic liver disease. Each surviving member was contacted annually, and medical records for all hospitalizations that occurred since the last follow-up for those subjects who reported liver disease were collected and abstracted. The contacts ensured that any liver disease that may have been missed through enzyme screening, or which may have newly developed, would be identified.

The study was formerly supported by N01HB87047.

Study Design

Observational Model: Natural History


Hepatitis, Viral, Human




National Heart, Lung, and Blood Institute (NHLBI)

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:57:53-0400

Clinical Trials [1941 Associated Clinical Trials listed on BioPortfolio]

Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.

Little is known about the nature and extent of the disturbance in hepatic function and biliary hepatic clearance in chronic viral hepatitis, while the course of this disease, the functiona...

Maraviroc Efficacy for Hepatitis C

This is a single-site, longitudinal, open-label, interventional study for evaluating the effect of maraviroc on hepatitis C viral levels in patients infected with both hepatitis C and huma...

Analysis of Trends Over Time of Hepatitis Related Incidence in Panama

The purpose of this study is to analyze the incidence of baseline hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) together with the current frequency of the ...

Acute Viral Hepatitis and Diabetes Mellitus

It has been observed that several of patients having prolonged or complicated course of acute viral hepatitis have underlying diabetes. It is possible that with impaired hepatocyte regener...

Risk of Post Transfusion Hepatitis C Virus Infection

To determine the risk of transfusion-transmitted hepatitis C virus (HCV) in cardiac surgery patients before and after donor screening for anti-HCV and surrogate markers of non-A, non-B hep...

PubMed Articles [12526 Associated PubMed Articles listed on BioPortfolio]

HDV evolution-will viral resistance be an issue in HDV infection?

Hepatitis D virus (HDV) is a hepatotropic subviral infectious agent, obligate satellite of the Hepatitis B virus (HBV) and is highly related to viroids. HDV affects around 5% of the 257 million chroni...

Introduction of universal infant hepatitis B immunisation in the UK- paving the way to elimination.

In May 2016, the World Health Assembly ratified the first ever Global Health Sector Strategy (GHSS) on Viral Hepatitis to eliminate viral hepatitis as a public health threat by 2030. In pursuit of thi...

Spontaneous Viral Clearance in Sixteen HIV-Infected Patients with Chronic Hepatitis C.

Spontaneous viral clearance of the chronic hepatitis C virus (HCV) in human immunodeficiency virus (HIV)-infected patients is a rare event. We aimed to identify the clinical, therapeutic, demographic,...

Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections.

While chronic infection with the human hepatitis B virus (HBV) and hepatitis delta virus (HDV) inflict major health burdens worldwide, current therapies cannot cure patients. One possible novel approa...

Pathogenesis of and New Therapies for Hepatitis D.

Hepatitis delta virus (HDV) infection of humans was first reported in 1977, and now it is now estimated that 15-20 million people are infected worldwide. Infection with HDV can be an acute or chronic ...

Medical and Biotech [MESH] Definitions

INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).

Any vaccine raised against any virus or viral derivative that causes hepatitis.

INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.

A species in the genus HEPATOVIRUS containing one serotype and two strains: HUMAN HEPATITIS A VIRUS and Simian hepatitis A virus causing hepatitis in humans (HEPATITIS A) and primates, respectively.

The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum.

More From BioPortfolio on "Natural History of Post-Transfusion Non-A, Non-B Hepatitis"

Quick Search


Relevant Topics

Hepatitis (plural hepatitides) is a medical condition defined by the inflammation of the liver and characterized by the presence of inflammatory cells in the tissue of the organ. The condition can be self-limiting (healing on its own) or can progress to ...

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Searches Linking to this Trial